Business
Evolus to Report First Quarter 2020 Financial Results and Provide a Business Update on Monday, May 11, 2020
NEWPORT BEACH, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"NEWPORT BEACH, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its first quarter 2020 financial results and provide a business update on Monday, May 11, 2020 after the close of the U.S. financial markets.\n Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question and answer session will follow management remarks. The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers. The conference ID is 1819528. A replay of the call will be available following its completion through May 18, 2020. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 1819528. A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call. About Evolus, Inc.Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com. Jeuveau® is a registered trademark of Evolus, Inc.Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Evolus, Inc. Contacts: Investor Contact:Ashwin AgarwalVice President, Finance, Investor Relations & TreasuryTel: +1-949-284-4559Email: [email protected] Media Contact:Crystal MuilenburgVice President, Corporate Communications & Public RelationsTel: +1-949-284-4506Email: [email protected] \n\n\nSource: Evolus","length":3920,"tagName":"div"}]